+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Host response to tissue engineered devices



Host response to tissue engineered devices



Advanced Drug Delivery Reviews 33(1-2): 111-139



The two main components of a tissue engineered device are the transplanted cells and the biomaterial, creating a device for the restoration or modification of tissue or organ function. The implantation of polymer/cell constructs combines concepts of biomaterials and cell transplantation. The interconnections between the host responses to the biomaterial and transplanted cells determines the biocompatibility of the device. This review describes the inflammatory response to the biomaterial component and immune response towards transplanted cells. Emphasis is on how the presence of the transplanted cell construct affects the host response. The inflammatory response towards a biomaterial can impact the immune response towards transplanted cells and vice versa. Immune rejection is the most important host response towards the cellular component of tissue engineered devices containing allogeneic, xenogeneic or immunogenic ex vivo manipulated autologous cells. The immune mechanisms towards allografts and xenografts are outlined to provide a basis for the mechanistic hypotheses of the immune response towards encapsulated cells, with antigen shedding and the indirect pathway of antigen presentation predominating. A review of experimental evidence illustrates examples of the inflammatory response towards biodegradable polymer scaffold materials, examples of devices appropriately integrated as assessed morphologically with the host for various applications including bone, nerve, and skin regeneration, and of the immune response towards encapsulated allogeneic and xenogeneic cells.

(PDF emailed within 1 workday: $29.90)

Accession: 046274915

Download citation: RISBibTeXText

PMID: 10837656


Related references

Host response to tissue engineered devices. Advanced Drug Delivery Reviews 33(1-2): 111-139, Aug 3, 1998

The Host Immune Response to Tissue-Engineered Organs: Current Problems and Future Directions. Tissue Engineering. Part B, Reviews 22(3): 208-219, 2015

Tissue-engineered devices in cardiovascular surgery. European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes 49(1): 44-52, 2012

Extracorporeal tissue engineered liver-assist devices. Annual Review of Biomedical Engineering 2: 607-632, 2001

Tissue-engineered repair of osteochondral defects: effects of the age of donor cells and host tissue. Tissue Engineering 8(6): 921-929, 2003

A tissue-engineered aneurysm model for evaluation of endovascular devices. Journal of Biomedical Materials Research. Part A 100(12): 3189-3196, 2013

Assessing infection risk in implanted tissue-engineered devices. Biomaterials 28(34): 5148-5154, 2007

Acellular dermal matrix and negative pressure wound therapy: a tissue-engineered alternative to free tissue transfer in the compromised host. Journal of Reconstructive Microsurgery 28(2): 139-144, 2012

Safety evaluation of tissue engineered medical devices using normal human mesenchymal stem cells. Yakugaku Zasshi 127(5): 851-856, 2007

Use of neopterin as a bone marrow hematopoietic and stromal cell growth factor in tissue-engineered devices. Advances in Experimental Medicine and Biology 585: 115-121, 2006

Tissue-engineered vascular grafts as in vitro blood vessel mimics for the evaluation of endothelialization of intravascular devices. Tissue Engineering 12(12): 3431-3438, 2007

Stereological methods to assess tissue response for tissue-engineered scaffolds. Biomaterials 28(2): 175-186, 2006

Tissue-engineered stent-graft integrates with aortic wall by recruiting host tissue into graft scaffold. Journal of Thoracic and Cardiovascular Surgery 148(4): 1719-1725, 2015

Local delivery of basic fibroblast growth factor increases both angiogenesis and engraftment of hepatocytes in tissue-engineered polymer devices. Transplantation 73(10): 1589-1593, 2002